Alzheimer's drug candidate BNC passes first safety check in healthy seniors
NCT ID NCT01747213
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a single dose of bisnorcymserine (BNC) in 75 healthy volunteers aged 55 and older to see how safe it is and how the body processes it. BNC is designed to block a brain chemical that may affect communication between nerve cells, potentially helping with Alzheimer's symptoms. Participants took either BNC or a placebo and were monitored for side effects and drug levels in the blood. The goal was to gather safety data before testing the drug in people with Alzheimer's disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbor Hospital Center
Baltimore, Maryland, United States
-
National Institute on Aging, Clinical Research Unit
Baltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A 10-second sprint may reveal who gains the most muscle from weight training
- Can a needle and a zap boost athletic performance? a trial puts five nerve-stimulation patterns to the test.
- Can an inhaled powder stop lung scarring? a safety trial begins
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Could a gentle buzz behind the ears tune your heart's rhythm?
- Training Non-Radiology staff to take X-Rays: a feasibility test